Kymera Therapeutics

OverviewSuggest Edit

Kymera Therapeutics is a biotechnology company aimed to create medicines for patients with previously untreatable diseases. The company specializes in the field of targeted protein degradation (TPD) accessing the body’s innate protein recycling machinery to degrade rather than inhibit dysregulated, disease-causing proteins. Its proprietary integrated degradation platform, Pegasus, consists of informatics-driven target identification, novel E3 ligases, proprietary ternary complex predictive modeling capabilities and degradation tools.

TypePrivate
Founded2017
HQCambridge, MA, US
Websitekymeratx.com

Latest Updates

Employees (est.) (Jan 2021)73(+8%)
Cybersecurity ratingAMore

Key People/Management at Kymera Therapeutics

Nello Mainolfi

Nello Mainolfi

Founder, President, Chief Executive Officer & Director
Jared Gollob

Jared Gollob

Chief Medical Officer
Bruce Jacobs

Bruce Jacobs

Chief Financial Officer
Richard Chesworth

Richard Chesworth

Chief Scientific Officer
Karen Martin

Karen Martin

Vice President, Head of Intellectual Property
Brian Albarran

Brian Albarran

Vice President, Strategy and Operations
Show more

Kymera Therapeutics Office Locations

Kymera Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
300 Tech Square, 300 Technology Square 2nd Floor
Show all (1)

Kymera Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2017

Kymera Therapeutics total Funding

$197 m

Kymera Therapeutics latest funding size

$102 m

Time since last funding

a year ago

Kymera Therapeutics investors

Kymera Therapeutics's latest funding round in March 2020 was reported to be $102 m. In total, Kymera Therapeutics has raised $197 m
Show all financial metrics

Kymera Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Kymera Therapeutics Online and Social Media Presence

Embed Graph

Kymera Therapeutics News and Updates

Kymera Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021

WATERTOWN, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will present at the virtual 39th Annual J.P.…

Kymera Therapeutics Announces Key Leadership Appointments

WATERTOWN, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel, small molecule protein degrader therapeutics, today announced the appointments of William Leong, PhD, as Vice President…

Kymera Therapeutics Presents Preclinical Data on IRAKIMiD and STAT3 Programs at Virtual 62nd American Society of Hematology (ASH) Annual Meeting

WATERTOWN, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel, small molecule protein degrader therapeutics, today announced the company presented preclinical data that further suppo…

Kymera Therapeutics to Present at the Piper Sandler 32nd Annual Healthcare Conference

WATERTOWN, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradati…

Kymera Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

WATERTOWN, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradati…

Kymera Therapeutics to Deliver Two Podium Presentations at 3rd Annual Targeted Protein Degradation Summit

WATERTOWN, Mass., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader therapeutics, will share two key presentations at the 3rd Annual Targeted Protein …
Show more

Kymera Therapeutics Blogs

62nd American Society of Hematology (ASH) Virtual Annual Meeting and Exposition, December 5-8, 2020

Poster Presentation: Targeting MYD88-Mutant DLBCL with IRAKIMiDs: A Comparison to IRAK4 Kinase Inhibition and Evaluation of Synergy with Rational Combinations The post 62nd American Society of Hematology (ASH) Virtual Annual Meeting and Exposition, December 5-8, 2020 appeared first on Kymera Therape…

Becoming CEO: The First 18 Months

I’ve held many titles and even more roles at Kymera since founding the company with Bruce Booth and Atlas Venture four years ago. But it’s been just over 12 months since we announced my appointment to CEO, and nearly 18 months in the role. Looking back now, I could not imagine a more challenging and…

IRAK4 Degrader to Take on Innate Immunity, November 3, 2020

Mullard, A. IRAK4 degrader to take on innate immunity. Nat Biotechnol 38, 1221–1223 (2020). https://doi.org/10.1038/s41587-020-0724-8 The post IRAK4 Degrader to Take on Innate Immunity, November 3, 2020 appeared first on Kymera Therapeutics.

3rd Annual Targeted Protein Degradation (TPD) Summit, Dr. Mainolfi, October 13-15, 2020

Oral Presentation: Targeted Protein Degradation Beyond Oncology The post 3rd Annual Targeted Protein Degradation (TPD) Summit, Dr. Mainolfi, October 13-15, 2020 appeared first on Kymera Therapeutics.

3rd Annual Targeted Protein Degradation (TPD) Summit, October 13-15, 2020

Oral Presentation: PK/PD Relationship in Targeted Protein Degradation The post 3rd Annual Targeted Protein Degradation (TPD) Summit, October 13-15, 2020 appeared first on Kymera Therapeutics.

5th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA), October 9-11, 2020

Poster Presentation: Interim results from non-interventional study to evaluate cutaneous and circulating biomarkers for a novel IRAK4-targeted therapeutic in patients with hidradenitis suppurativa The post 5th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA), October 9-11, 2020 appeared …
Show more

Kymera Therapeutics Frequently Asked Questions

  • When was Kymera Therapeutics founded?

    Kymera Therapeutics was founded in 2017.

  • Who are Kymera Therapeutics key executives?

    Kymera Therapeutics's key executives are Nello Mainolfi, Jared Gollob and Bruce Jacobs.

  • How many employees does Kymera Therapeutics have?

    Kymera Therapeutics has 73 employees.

  • Who are Kymera Therapeutics competitors?

    Competitors of Kymera Therapeutics include Foghorn Therapeutics, Urovant Sciences and Rubius Therapeutics.

  • Where is Kymera Therapeutics headquarters?

    Kymera Therapeutics headquarters is located at 300 Tech Square, 300 Technology Square 2nd Floor, Cambridge.

  • Where are Kymera Therapeutics offices?

    Kymera Therapeutics has an office in Cambridge.

  • How many offices does Kymera Therapeutics have?

    Kymera Therapeutics has 1 office.